EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

High Dose Rate Brachytherapy as a Treatment Option in Endobronchial Tumors

Ali Hosni, Andrea Bezjak iD, Alexandra Rink, Kasia Czarnecka, Andrew McPartlin, Susan Patterson, Elantholiparameswaran Saibishkumar

Lung Cancer International · 2016

DOI: 10.1155/2016/3086148 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Lung Cancer International, 2016. Verfasst von Ali Hosni und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, 610 University Avenue, Toronto, ON, Canada M5G 2M9. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To report our experience with high dose rate endobronchial brachytherapy (HDR-EBBT) and to assess its efficacy and tolerability with possibility of its use in selected cases with curative intent.

Method

Retrospective review of patients with endobronchial tumors treated at our institution in 2007–2013 with HDR-EBBT. Subjective response and treatment related toxicity were extracted from patients’ records. Clinical response was evaluated by chest CT +/− bronchoscopy 2-3 months after treatment. Local control (LC) and overall survival (OS) were analyzed.

Results

Overall 23 patients were identified. Ten patients were treated with curative intent, in 8 of them HDR-EBBT was combined with external beam radiotherapy. Short term palliation was as follows: dyspnea (13/15), cough (12/14), and hemoptysis (3/3). Seventeen patients were evaluated, of whom 9 (53%) showed complete response. Four patients developed local failure (only 1 of them treated with curative intent) and were salvaged with HDR-EBBT ( n = 1 ), chemotherapy ( n = 2 ), and laser ( n = 1 ). Among patients treated with curative intent, the 2-year LC and OS were 89% and 67%, respectively, and 2 out of 4 deaths were cancer-related. Late toxicity included bronchial stenosis ( n = 1 ). Only 1 patient had fatal hemoptysis and postmortem examination indicated local recurrence.

Conclusion

HDR-EBBT is promising treatment with tolerable complication if used in properly selected patients.

Autor:innen und Institutionen

  • Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, 610 University Avenue, Toronto, ON, Canada M5G 2M9.
  • Division of Respirology and Thoracic Surgery, University Health Network, Toronto, ON, Canada.
  • Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON, Canada.

ORCID-Profile: Andrea Bezjak

Zitieren

APA

Hosni, A., Bezjak, A., Rink, A., Czarnecka, K., McPartlin, A., Patterson, S., & Saibishkumar, E. (2016). High Dose Rate Brachytherapy as a Treatment Option in Endobronchial Tumors. Lung Cancer International. https://doi.org/10.1155/2016/3086148

Vancouver

Hosni A, Bezjak A, Rink A, Czarnecka K, McPartlin A, Patterson S, et al. High Dose Rate Brachytherapy as a Treatment Option in Endobronchial Tumors. Lung Cancer International. 2016. doi:10.1155/2016/3086148

BibTeX
@article{Hosni2016,
  author = {Hosni, Ali and Bezjak, Andrea and Rink, Alexandra and Czarnecka, Kasia and McPartlin, Andrew and Patterson, Susan and Saibishkumar, Elantholiparameswaran},
  title = {High Dose Rate Brachytherapy as a Treatment Option in Endobronchial Tumors},
  journal = {Lung Cancer International},
  year = {2016},
  doi = {10.1155/2016/3086148}
}
Kostenlos starten →